Wave Life Sciences Ltd. 8-K

What Happened

• On May 18, 2026, Wave Life Sciences Ltd. (Wave) filed an 8-K under Regulation FD to announce a positive update from the ongoing RestorAATion-2 trial of WVE-006, its investigational GalNAc‑conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) for alpha-1 antitrypsin deficiency (AATD). The company issued a press release (attached as Exhibit 99.1) and said management will host an investor conference call at 5:30 p.m. ET on May 18, 2026 to review the program and updated clinical data.

Key Details

• Filing date: May 18, 2026 (Form 8-K, Regulation FD disclosure).
• Program: RestorAATion-2 trial of WVE-006 (investigational GalNAc‑conjugated, subcutaneous RNA editing oligonucleotide for AATD).
• Investor call: 5:30 p.m. ET on May 18, 2026; a slide presentation will be available on Wave’s Investors webpage (https://ir.wavelifesciences.com/).
• Press release attached as Exhibit 99.1 to the 8-K.

Why It Matters

• The company publicly disclosed a positive clinical update and scheduled an investor call to share updated data and slides, giving investors direct access to management’s presentation of the RestorAATion-2 program. This is a material operational update about WVE-006’s clinical progress and is being shared under Regulation FD for broad disclosure.